This is not the most recent version of the article. View current version (19 MAY 2015)

Intervention Protocol

You have free access to this content

Concurrent chemoradiotherapy with weekly versus three-weekly cisplatin in locally advanced head and neck squamous cell carcinoma

  1. Thiagarajan Shivakumar1,*,
  2. Sudhir Nair2,
  3. Tejpal Gupta3,
  4. Sadhana Kannan4

Editorial Group: Cochrane Ear, Nose and Throat Disorders Group

Published Online: 10 JAN 2014

DOI: 10.1002/14651858.CD010906


How to Cite

Shivakumar T, Nair S, Gupta T, Kannan S. Concurrent chemoradiotherapy with weekly versus three-weekly cisplatin in locally advanced head and neck squamous cell carcinoma (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010906. DOI: 10.1002/14651858.CD010906.

Author Information

  1. 1

    Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Surgical Oncology (Head & Neck Services), Navi Mumbai, India

  2. 2

    Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, Surgical Oncology, Navi Mumbai, India

  3. 3

    Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, Radiation Oncology, Navi Mumbai, India

  4. 4

    Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, Clinical Research Secretariat/Epidemiology & Clinical Trial Unit, Navi Mumbai, India

*Thiagarajan Shivakumar, Surgical Oncology (Head & Neck Services), Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, India. drshiva78in@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 10 JAN 2014

SEARCH

This is not the most recent version of the article. View current version (19 MAY 2015)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Primary objective

To assess the efficacy of a weekly cisplatin regimen compared to a three-weekly regimen, given with curative intent to treat locally advanced HNSCC, in terms of overall survival (at five years).

Secondary objective

To assess the distant metastasis-free survival (at two years), disease-free survival (at two years) and the toxicity profile of the two regimens.